These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35256306)

  • 1. Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over.
    Alicandro G; Daccó V; Cariani L; Contarini M; Morlacchi LC; Rosazza C; Sciarrabba CS; Ferraro F; Lanfranchi C; Orena BS; Gramegna A; Blasi F; Colombo C
    J Cyst Fibros; 2022 May; 21(3):e173-e175. PubMed ID: 35256306
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
    Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
    Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection.
    Stellini R; Gianello R; Meloni A; Croce E; Materzanini P; Gomarasca W
    Infection; 2022 Jun; 50(3):791-793. PubMed ID: 34855188
    [No Abstract]   [Full Text] [Related]  

  • 4. Immediate reactions after mRNA SARS-CoV-2 vaccination.
    Jeimy S; Wong T; Song C
    CMAJ; 2021 Dec; 193(48):E1842. PubMed ID: 34772737
    [No Abstract]   [Full Text] [Related]  

  • 5. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study.
    Haslak F; Gunalp A; Cebi MN; Yildiz M; Adrovic A; Sahin S; Barut K; Kasapcopur O
    Int J Rheum Dis; 2022 Mar; 25(3):353-363. PubMed ID: 34978376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine.
    Wang M; Wen W; Zhou M; Wang C; Feng ZH
    Am J Cardiol; 2022 Mar; 167():155-157. PubMed ID: 35063268
    [No Abstract]   [Full Text] [Related]  

  • 7. Definite Acute Myocarditis After Coronavirus Disease 2019 mRNA Vaccination.
    Maeda M; Isawa T; Tada N
    Circ J; 2022 Mar; 86(4):724. PubMed ID: 34866122
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronavirus disease 2019 messenger RNA vaccine skin tests and serum histamine levels in allergic reactions.
    Kohli-Pamnani A; Zapata K; Gibson T; Kwittken PL
    Ann Allergy Asthma Immunol; 2022 Mar; 128(3):339. PubMed ID: 35216745
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine.
    Zeng G
    Lancet Microbe; 2022 Aug; 3(8):e561. PubMed ID: 35659883
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety of mRNA-Based Vaccines for SARS CoV-2.
    Barda B; Cerny A
    Chem Res Toxicol; 2021 Aug; 34(8):1823-1825. PubMed ID: 34009959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalent humoral and cellular immune response but different side effect rates following SARS-CoV-2 vaccination in peritoneal and haemodialysis patients using messenger RNA vaccines.
    Stumpf J; Klimova A; Mauer R; Steglich A; Gembardt F; Martin H; Glombig G; Frank K; Tonn T; Hugo C
    Nephrol Dial Transplant; 2022 Mar; 37(4):796-798. PubMed ID: 34791446
    [No Abstract]   [Full Text] [Related]  

  • 13. COVID-19 mRNA Vaccine Short-Term Safety in Patients With Inflammatory Bowel Disease.
    Spiera E; Agrawal M; Ungaro RC
    Gastroenterology; 2022 Mar; 162(3):987-988. PubMed ID: 34626602
    [No Abstract]   [Full Text] [Related]  

  • 14. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
    Masuda T; Murakami K; Sugiura K; Sakui S; Philip Schuring R; Mori M
    Vaccine; 2022 Mar; 40(13):2044-2052. PubMed ID: 35177302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
    Greenberg RS; Ruddy JA; Boyarsky BJ; Werbel WA; Garonzik-Wang JM; Segev DL; Imus PH
    BMC Cancer; 2021 Dec; 21(1):1354. PubMed ID: 34961488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients.
    Masset C; Benotmane I; Dantal J; Garandeau C; Gauthier-Vargas G; Cantarovich D; Meurette A; Giral M; Caillard S; Blancho G
    Kidney Int; 2022 Apr; 101(4):825-826. PubMed ID: 35167873
    [No Abstract]   [Full Text] [Related]  

  • 17. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines.
    Szebeni J; Storm G; Ljubimova JY; Castells M; Phillips EJ; Turjeman K; Barenholz Y; Crommelin DJA; Dobrovolskaia MA
    Nat Nanotechnol; 2022 Apr; 17(4):337-346. PubMed ID: 35393599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urticarial vasculitis triggered by SARS-CoV-2 vaccine (mRNA vaccine).
    Daldoul M; Korbi M; Bellalah A; Ben Fadhel N; Belhadjali H; Zili J
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):e743-e744. PubMed ID: 35604050
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.